Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a phase Ib study
This study indicated a DDI between ipatasertib and palbociclib, leading to increased ipatasertib exposure. The combination regimen of ipatasertib 300 mg with palbociclib and fulvestrant had a notable and manageable safety profile, that is generally consistent with the known risks of each individual study drugs in patients with HR + HER2-breast cancer.
Authors
- Victor Poon (ORCID: https://orcid.org/0000-0002-4215-2198)
- Rucha Sane (ORCID: https://orcid.org/0000-0002-9043-5336)
- Ryan Johnson (ORCID: https://orcid.org/0000-0003-0586-9955)
- Frauke Schimmöller
- Ksenia Arzumanova
- Kit Wun Kathy Cheung (ORCID: https://orcid.org/0000-0002-5541-3617)
- Adam Harris (ORCID: https://orcid.org/0009-0009-4154-8017)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-09-26
- DOI
- https://doi.org/10.3389/fphar.2025.1670582
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer